Belamaf
(Belantamab)Phase 3Monoclonal antibody
GSKBelantamab is used to treat multiple myeloma, a type of blood cancer where abnormal plasma cells multiply in the bone marrow. It works by targeting and destroying cancer cells that have a specific protein on their surface.[1] Belamaf is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Belamaf is one of 138 biologic programs targeting Amyloidosis. It is currently in Phase 3.
9
Indications
61
Total Trials
38
Active Trials
137
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
259 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Belamaf
GSKPhase 3
Biaxin
AbbViePhase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Sylvant
RRECORDATI GROUP
Phase 3
Linvoseltamab
RegeneronPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma39 trials
Show 36 more trials
ART3 trials
Plasma Cell Myeloma3 trials
Monotherapy2 trials
Recurrent Multiple Myeloma2 trials
12 more indications
Dexamethasone1 trial
Lenalidomide1 trial
Autoimmune Disease1 trial
Immune Thrombocytopenia1 trial
Amyloidosis1 trial
Myeloma Multiple1 trial
Myeloma1 trial
Relapsed/Refractory Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Belantamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]